The tumor necrosis factor-α inhibitor golimumab in the treatment of rheumatoid arthritis
The tumor necrosis factor-α (TNF-α) golimumab (GLM), that is a fully human monoclonal anti-body, was registered in Russia in 2012 to treat rheumatic diseases, such as rheumatoid arthritis (RA), ankylosing spondylitis, and psoriatic arthritis. Its distinguishing characteristics are a high affinity fo...
Main Author: | |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2014-12-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/579 |